Mosanna raises €72.0M Series A round
9 June 2025· Basel, Switzerland· health, biotech, pharmaceuticals, drug_discovery, b2b
The funding will support the advancement of Mosanna's lead therapy, MOS118 (a nighttime nasal spray for obstructive sleep apnea), through Phase 2 clinical trials and also support the expansion of Mosanna's product pipeline.
Investors
LeadPivotal bioVenture Partners
Also participating
High-Tech Gründerfonds (HTGF)EQT Life SciencesForbionBroadview VenturesNorwestForty51 VenturesSupermoon Capital
About Mosanna
Stage
Series A
Headquarters
Basel, Switzerland
Founded
2022
Sectors
healthbiotechpharmaceuticalsdrug_discoveryb2b